BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 09, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Undisclosed HuCal antibody for ophthalmology: Phase I started

Novartis began a Phase I trial of an undisclosed HuCAL antibody. The start triggers an undisclosed milestone payment to MorphoSys, which is using...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >